{"success":true,"data":{"pressRelease":{"id":"142571","rtpr_id":"nGNXS2yhR-20260914","ticker":"AVXL","exchange":"NASDAQ","all_tickers":["AVXL"],"title":"Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees","author":"Globe Newswire","published_at":"2026-09-14T12:30:00.700Z","article_body":"ISS Recognizes There is No Case for Change\n\nAnavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR”\nALL Six Director Nominees on the WHITE Proxy Card Today\n\nNEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.\n(“Anavex” or “the Company”), a clinical-stage biopharmaceutical\ncompany focused on developing innovative treatments for central nervous system\ndiseases with high unmet medical needs, today announced that leading\nindependent proxy advisory firm Institutional Shareholder Services (“ISS”)\nhas recommended that Anavex stockholders vote on the WHITE proxy card\n“FOR” all six of the Company’s highly qualified director nominees\nstanding for election at the 2026 Annual Meeting of Stockholders – Dr. Jiong\nMa, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian\nSenderowicz and Dr. Claus van der Velden.\n\nIn its report issued on September 11, 2026, ISS noted the substantive plan and\nstrategy underway at Anavex and concluded that “[t]he dissident has not made\na compelling case for change.”(1)\n\nIn recommending “FOR” all six of the Anavex nominees on the WHITE proxy\ncard, ISS also stated(2):\n* “[The EMA opinion] appears to have been a turning point, after which the\nboard assumed a more active role that resulted in removal of the CEO.” \n\n\n* “Since then, the board has also refreshed. Half of the board, when new\nnominees are included, is now composed of new members. It appears that the new\nboard members bring experience in drug development, early-stage company\ndevelopment, and an understanding of the FDA approval process.”\n\n\n* “The board also appointed an interim CEO and is moving towards hiring a\npermanent CEO, CFO, and CMO.”\n \n\n* “Starting with the formation of the special committee and subsequent\ntermination of the former CEO, the board appears to have acted decisively to\nremedy a situation that it admits was of its own making.”\nThe Executive Committee of Anavex’s Board issued the following statement:\n\nISS’ recommendation reaffirms that we have the right slate of Board nominees\nto continue driving long-term stockholder value and overseeing our new,\nfocused strategy.\n\nOur six nominees bring the biotechnology, clinical research, pharmaceutical\ndevelopment, regulatory and public company experience Anavex needs at this\nstage, and, if elected, half the Board will have been refreshed since the\nbeginning of 2026, with every director as independent.\n\nISS agrees that “despite seeking a majority position, [PVG] has not\npresented a detailed go-forward plan.”(3) We believe PVG’s slate,\nconcentrated in investment management and equity research, would leave Anavex\nflailing and without focus, overseen by a Board deficient in the expertise\nthat matters most.\n\nWe are grateful that ISS, after an independent review of both sides, is\nrecommending “FOR” all six of our director nominees. We believe PVG’s\nattempt to seize control of the Board would disrupt Anavex’s progress at\nexactly the wrong moment for patients and stockholders alike.\n\nAnavex strongly encourages all stockholders to follow ISS’ guidance and vote\n“FOR” ALL six of Anavex’s director nominees standing for election on\ntheir WHITE proxy card. For additional information on Anavex’s nominees and\nhow to vote, visit www.VoteAnavex.com.\n\nThe Annual Meeting will be held on September 24, 2026, and stockholders of\nrecord as of the close of business on July 31, 2026 are entitled to vote.\n\nAnavex stockholders with questions about or requiring assistance with voting\nshares, please call:\n\nInnisfree M&A Incorporated\n500 Fifth Avenue, 21(st) Floor\nNew York, NY 10110\nStockholders may call toll-free at (877) 750-0831\nBrokers, banks and other nominees may call collect at (212) 750-5833\n\nAbout Anavex Life Sciences Corp.\n\nAnavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded\nbiopharmaceutical company dedicated to the development of novel therapeutics\nfor the treatment of neurodegenerative, neurodevelopmental, and\nneuropsychiatric disorders. Further information is available\nat www.anavex.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements that are not\nhistorical facts, including statements regarding the Company's plans,\nstrategies and expectations regarding the 2026 Annual Meeting, director\nnominations, the proxy solicitation, the Company's go-forward strategy,\nclinical development programs, business prospects, and potential actions of\nthe Board and the Executive Committee, are forward-looking statements. These\nstatements can be identified by the use of forward-looking terminology,\nincluding the words \"believes,\" \"anticipates,\" \"plans,\" \"estimates,\"\n\"expects,\" \"intends,\" \"may,\" \"will,\" \"would,\" \"could\" and similar expressions,\nor the negative thereof. Many factors may cause actual results to differ\nmaterially from those projected in any of such forward-looking statements,\nincluding the risks and uncertainties set forth in the Company's Annual Report\non Form 10-K for the fiscal year ended September 30, 2025, filed with the\nSecurities and Exchange Commission (\"SEC\") on November 25, 2025, the Company's\nQuarterly Report on Form 10-Q for the quarterly period ended December 31,\n2025, filed with the SEC on February 9, 2026, the Company's Form 10-K/A for\nthe fiscal year ended September 30, 2025, filed with the SEC on August 28,\n2026, the Company's Form 10-Q/A for the quarterly period ended December 31,\n2025, filed with the SEC on August 28, 2026, the Company's Quarterly Report on\nForm 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on\nAugust 28, 2026, the Company's Quarterly Report on Form 10-Q for the quarterly\nperiod ended June 30, 2026, filed with the SEC on August 28, 2026, and\nsubsequent filings and furnishings with the SEC, which should be considered\ntogether with any forward-looking statement. Readers are cautioned not to\nplace undue reliance on these forward-looking statements, which speak only as\nof the date hereof. All forward-looking statements are qualified in their\nentirety by this cautionary statement, and Anavex Life Sciences Corp.\nundertakes no obligation to revise or update this press release to reflect\nevents or circumstances after the date hereof except as required by law.\n\nImportant Additional Information and Where to Find It\nThe Company has filed a definitive proxy statement on Schedule 14A, an\naccompanying WHITE proxy card, and other relevant documents with the SEC in\nconnection with the solicitation of proxies from the Company's stockholders\nfor the 2026 Annual Meeting. THE COMPANY'S STOCKHOLDERS ARE STRONGLY\nENCOURAGED TO READ THE COMPANY'S DEFINITIVE PROXY STATEMENT (INCLUDING ANY\nAMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND\nOTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE\nTHEY CONTAIN IMPORTANT INFORMATION. Stockholders are able to obtain the\ndefinitive proxy statement, any amendments or supplements to the proxy\nstatement and other documents that the Company files with the SEC at no charge\nat the SEC's website at www.sec.gov. Copies are also available at no charge at\nthe Company's website at www.anavex.com.\n\nCertain Information Regarding Participants\nThe Company, its directors and certain of its executive officers may be deemed\nto be \"participants\" (as defined in Schedule 14A under the Securities Exchange\nAct of 1934, as amended) in the solicitation of proxies from the Company's\nstockholders in connection with the matters to be considered at the 2026\nAnnual Meeting. Information regarding the names of the Company's directors and\nexecutive officers and certain other individuals and their direct or indirect\ninterests in the Company, by security holdings or otherwise, is set forth in\nthe sections entitled \"Compensation of Directors,\" \"Executive Compensation,\"\nand \"Security Ownership of Certain Beneficial Owners and Management and\nRelated Stockholder Matters\" of the Company's Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2025 (available here), and any subsequent\nfilings on Forms 3, 4 and 5 filed with the SEC. Additional information\nregarding the identity of potential participants, and their direct or indirect\ninterests, by security holdings or otherwise, is set forth in the Company's\ndefinitive proxy statement for the 2026 Annual Meeting which has been filed\nwith the SEC. These documents are available free of charge at the SEC's\nwebsite at www.sec.gov.\n\nInvestor Relations:\nSCR Partners, LLC\nAlex Arzeno\nTel: 203-550-3972\nEmail: alex@scr-ir.com\n\nTripp Sullivan\nTel: 615-942-7077\nEmail: tsullivan@scr-ir.com\n\nFor Media:\nCollected Strategies\nNick Lamplough / Dylan O’Keefe\nAVXL-CS@collectedstrategies.com\n\n_________________________________\n(1) Permission to use quotations neither sought nor obtained.\n(2) Permission to use quotations neither sought nor obtained.\n(3) Permission to use quotations neither sought nor obtained.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1b0f858f-4f7f-4f50-b691-a25307283fb5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXS2yhR-20260914","title":"Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees","author":"Globe Newswire","ticker":"AVXL","created":"2026-09-14T12:30:00.700Z","tickers":["AVXL"],"exchange":"NASDAQ","article_body":"ISS Recognizes There is No Case for Change\n\nAnavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR”\nALL Six Director Nominees on the WHITE Proxy Card Today\n\nNEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.\n(“Anavex” or “the Company”), a clinical-stage biopharmaceutical\ncompany focused on developing innovative treatments for central nervous system\ndiseases with high unmet medical needs, today announced that leading\nindependent proxy advisory firm Institutional Shareholder Services (“ISS”)\nhas recommended that Anavex stockholders vote on the WHITE proxy card\n“FOR” all six of the Company’s highly qualified director nominees\nstanding for election at the 2026 Annual Meeting of Stockholders – Dr. Jiong\nMa, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian\nSenderowicz and Dr. Claus van der Velden.\n\nIn its report issued on September 11, 2026, ISS noted the substantive plan and\nstrategy underway at Anavex and concluded that “[t]he dissident has not made\na compelling case for change.”(1)\n\nIn recommending “FOR” all six of the Anavex nominees on the WHITE proxy\ncard, ISS also stated(2):\n* “[The EMA opinion] appears to have been a turning point, after which the\nboard assumed a more active role that resulted in removal of the CEO.” \n\n\n* “Since then, the board has also refreshed. Half of the board, when new\nnominees are included, is now composed of new members. It appears that the new\nboard members bring experience in drug development, early-stage company\ndevelopment, and an understanding of the FDA approval process.”\n\n\n* “The board also appointed an interim CEO and is moving towards hiring a\npermanent CEO, CFO, and CMO.”\n \n\n* “Starting with the formation of the special committee and subsequent\ntermination of the former CEO, the board appears to have acted decisively to\nremedy a situation that it admits was of its own making.”\nThe Executive Committee of Anavex’s Board issued the following statement:\n\nISS’ recommendation reaffirms that we have the right slate of Board nominees\nto continue driving long-term stockholder value and overseeing our new,\nfocused strategy.\n\nOur six nominees bring the biotechnology, clinical research, pharmaceutical\ndevelopment, regulatory and public company experience Anavex needs at this\nstage, and, if elected, half the Board will have been refreshed since the\nbeginning of 2026, with every director as independent.\n\nISS agrees that “despite seeking a majority position, [PVG] has not\npresented a detailed go-forward plan.”(3) We believe PVG’s slate,\nconcentrated in investment management and equity research, would leave Anavex\nflailing and without focus, overseen by a Board deficient in the expertise\nthat matters most.\n\nWe are grateful that ISS, after an independent review of both sides, is\nrecommending “FOR” all six of our director nominees. We believe PVG’s\nattempt to seize control of the Board would disrupt Anavex’s progress at\nexactly the wrong moment for patients and stockholders alike.\n\nAnavex strongly encourages all stockholders to follow ISS’ guidance and vote\n“FOR” ALL six of Anavex’s director nominees standing for election on\ntheir WHITE proxy card. For additional information on Anavex’s nominees and\nhow to vote, visit www.VoteAnavex.com.\n\nThe Annual Meeting will be held on September 24, 2026, and stockholders of\nrecord as of the close of business on July 31, 2026 are entitled to vote.\n\nAnavex stockholders with questions about or requiring assistance with voting\nshares, please call:\n\nInnisfree M&A Incorporated\n500 Fifth Avenue, 21(st) Floor\nNew York, NY 10110\nStockholders may call toll-free at (877) 750-0831\nBrokers, banks and other nominees may call collect at (212) 750-5833\n\nAbout Anavex Life Sciences Corp.\n\nAnavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded\nbiopharmaceutical company dedicated to the development of novel therapeutics\nfor the treatment of neurodegenerative, neurodevelopmental, and\nneuropsychiatric disorders. Further information is available\nat www.anavex.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements that are not\nhistorical facts, including statements regarding the Company's plans,\nstrategies and expectations regarding the 2026 Annual Meeting, director\nnominations, the proxy solicitation, the Company's go-forward strategy,\nclinical development programs, business prospects, and potential actions of\nthe Board and the Executive Committee, are forward-looking statements. These\nstatements can be identified by the use of forward-looking terminology,\nincluding the words \"believes,\" \"anticipates,\" \"plans,\" \"estimates,\"\n\"expects,\" \"intends,\" \"may,\" \"will,\" \"would,\" \"could\" and similar expressions,\nor the negative thereof. Many factors may cause actual results to differ\nmaterially from those projected in any of such forward-looking statements,\nincluding the risks and uncertainties set forth in the Company's Annual Report\non Form 10-K for the fiscal year ended September 30, 2025, filed with the\nSecurities and Exchange Commission (\"SEC\") on November 25, 2025, the Company's\nQuarterly Report on Form 10-Q for the quarterly period ended December 31,\n2025, filed with the SEC on February 9, 2026, the Company's Form 10-K/A for\nthe fiscal year ended September 30, 2025, filed with the SEC on August 28,\n2026, the Company's Form 10-Q/A for the quarterly period ended December 31,\n2025, filed with the SEC on August 28, 2026, the Company's Quarterly Report on\nForm 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on\nAugust 28, 2026, the Company's Quarterly Report on Form 10-Q for the quarterly\nperiod ended June 30, 2026, filed with the SEC on August 28, 2026, and\nsubsequent filings and furnishings with the SEC, which should be considered\ntogether with any forward-looking statement. Readers are cautioned not to\nplace undue reliance on these forward-looking statements, which speak only as\nof the date hereof. All forward-looking statements are qualified in their\nentirety by this cautionary statement, and Anavex Life Sciences Corp.\nundertakes no obligation to revise or update this press release to reflect\nevents or circumstances after the date hereof except as required by law.\n\nImportant Additional Information and Where to Find It\nThe Company has filed a definitive proxy statement on Schedule 14A, an\naccompanying WHITE proxy card, and other relevant documents with the SEC in\nconnection with the solicitation of proxies from the Company's stockholders\nfor the 2026 Annual Meeting. THE COMPANY'S STOCKHOLDERS ARE STRONGLY\nENCOURAGED TO READ THE COMPANY'S DEFINITIVE PROXY STATEMENT (INCLUDING ANY\nAMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND\nOTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE\nTHEY CONTAIN IMPORTANT INFORMATION. Stockholders are able to obtain the\ndefinitive proxy statement, any amendments or supplements to the proxy\nstatement and other documents that the Company files with the SEC at no charge\nat the SEC's website at www.sec.gov. Copies are also available at no charge at\nthe Company's website at www.anavex.com.\n\nCertain Information Regarding Participants\nThe Company, its directors and certain of its executive officers may be deemed\nto be \"participants\" (as defined in Schedule 14A under the Securities Exchange\nAct of 1934, as amended) in the solicitation of proxies from the Company's\nstockholders in connection with the matters to be considered at the 2026\nAnnual Meeting. Information regarding the names of the Company's directors and\nexecutive officers and certain other individuals and their direct or indirect\ninterests in the Company, by security holdings or otherwise, is set forth in\nthe sections entitled \"Compensation of Directors,\" \"Executive Compensation,\"\nand \"Security Ownership of Certain Beneficial Owners and Management and\nRelated Stockholder Matters\" of the Company's Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2025 (available here), and any subsequent\nfilings on Forms 3, 4 and 5 filed with the SEC. Additional information\nregarding the identity of potential participants, and their direct or indirect\ninterests, by security holdings or otherwise, is set forth in the Company's\ndefinitive proxy statement for the 2026 Annual Meeting which has been filed\nwith the SEC. These documents are available free of charge at the SEC's\nwebsite at www.sec.gov.\n\nInvestor Relations:\nSCR Partners, LLC\nAlex Arzeno\nTel: 203-550-3972\nEmail: alex@scr-ir.com\n\nTripp Sullivan\nTel: 615-942-7077\nEmail: tsullivan@scr-ir.com\n\nFor Media:\nCollected Strategies\nNick Lamplough / Dylan O’Keefe\nAVXL-CS@collectedstrategies.com\n\n_________________________________\n(1) Permission to use quotations neither sought nor obtained.\n(2) Permission to use quotations neither sought nor obtained.\n(3) Permission to use quotations neither sought nor obtained.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1b0f858f-4f7f-4f50-b691-a25307283fb5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-14T12:30:00.739902482Z","server_sent_at_ms":1789389000739},"received_at":"2026-09-14T12:30:00.794Z","source_url":null},"analysis":{"id":"131403","press_release_id":"142571","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Active proxy contest: dissident PVG is seeking majority board control less than two weeks before the September 24 vote","Former CEO was terminated; an interim CEO is in place with permanent CEO, CFO, and CMO searches still underway","Company filed an amended 10-K/A and multiple amended 10-Q/A filings on August 28, 2026, indicating prior filings were corrected or restated"],"eventType":"board_change","narrative":"Institutional Shareholder Services recommended that Anavex stockholders vote FOR all six of the company's director nominees on the WHITE proxy card ahead of the September 24, 2026 annual meeting, concluding the dissident has not made a compelling case for change.\n\nIn its September 11 report, ISS credited the board's post-EMA-opinion reset: the former CEO was terminated, half the board is refreshed once the nominees are elected, and an interim CEO is in place while the board hires a permanent CEO, CFO, and CMO.\n\nISS also said activist PVG, despite seeking a majority board position, has not presented a detailed go-forward plan; Anavex urged stockholders of record as of July 31, 2026 to follow the recommendation.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"ISS backs all six Anavex directors and calls out PVG's lack of a plan, a major win for the incumbent board days before the September 24 proxy vote."},"keyFigures":{"customDimensions":{"record_date":"July 31, 2026","board_refresh":"half of the board composed of new members once nominees are elected","iss_report_date":"September 11, 2026","director_nominees":6,"annual_meeting_date":"September 24, 2026"}},"quotedText":"[t]he dissident has not made a compelling case for change","namedEntities":{"people":[{"name":"Dr. Jiong Ma","role":"director nominee"},{"name":"Dr. Peter Donhauser","role":"director nominee"},{"name":"Dr. Axel Paeger","role":"director nominee"},{"name":"Mr. Gautam Patel","role":"director nominee"},{"name":"Dr. Adrian Senderowicz","role":"director nominee"},{"name":"Dr. Claus van der Velden","role":"director nominee"}],"products":[],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"filer / issuer"},{"name":"Institutional Shareholder Services (ISS)","relationship":"proxy advisory firm endorsing incumbent slate"},{"name":"PVG","relationship":"dissident activist seeking majority board control"},{"name":"Innisfree M&A Incorporated","relationship":"proxy solicitor"},{"name":"SCR Partners, LLC","relationship":"investor relations"},{"name":"Collected Strategies","relationship":"media relations"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"ISS endorsement of the full incumbent slate is a meaningful momentum shift in an active proxy contest, materially improving the board's odds ahead of the September 24 vote; however, it is a governance event with no direct financial impact, so it does not reach the 4-5 tier."},"tickerRelevance":{"others":[],"primary":"AVXL"},"globalImportance":24,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","votePending":"2026-09-24 annual meeting outcome still unresolved","eventGravity":"ISS endorsement in contested board election","sectorWeight":"biotech governance event, limited direct financial impact","retailFavoriteBoost":"AVXL has an active retail following; proxy fights draw elevated retail attention"}},"event_type":"board_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Institutional Shareholder Services recommended that Anavex stockholders vote FOR all six of the company's director nominees on the WHITE proxy card ahead of the September 24, 2026 annual meeting, concluding the dissident has not made a compelling case for change.\n\nIn its September 11 report, ISS credited the board's post-EMA-opinion reset: the former CEO was terminated, half the board is refreshed once the nominees are elected, and an interim CEO is in place while the board hires a permanent CEO, CFO, and CMO.\n\nISS also said activist PVG, despite seeking a majority board position, has not presented a detailed go-forward plan; Anavex urged stockholders of record as of July 31, 2026 to follow the recommendation.","key_figures":{"customDimensions":{"record_date":"July 31, 2026","board_refresh":"half of the board composed of new members once nominees are elected","iss_report_date":"September 11, 2026","director_nominees":6,"annual_meeting_date":"September 24, 2026"}},"named_entities":{"people":[{"name":"Dr. Jiong Ma","role":"director nominee"},{"name":"Dr. Peter Donhauser","role":"director nominee"},{"name":"Dr. Axel Paeger","role":"director nominee"},{"name":"Mr. Gautam Patel","role":"director nominee"},{"name":"Dr. Adrian Senderowicz","role":"director nominee"},{"name":"Dr. Claus van der Velden","role":"director nominee"}],"products":[],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"filer / issuer"},{"name":"Institutional Shareholder Services (ISS)","relationship":"proxy advisory firm endorsing incumbent slate"},{"name":"PVG","relationship":"dissident activist seeking majority board control"},{"name":"Innisfree M&A Incorporated","relationship":"proxy solicitor"},{"name":"SCR Partners, LLC","relationship":"investor relations"},{"name":"Collected Strategies","relationship":"media relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T12:31:26.367Z","global_importance":24,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","votePending":"2026-09-24 annual meeting outcome still unresolved","eventGravity":"ISS endorsement in contested board election","sectorWeight":"biotech governance event, limited direct financial impact","retailFavoriteBoost":"AVXL has an active retail following; proxy fights draw elevated retail attention"}},"durationMs":36560,"modelName":"glm-5.3-flash"}}